Logo

American Heart Association

  10
  0


Final ID: WP1

Intravenous Thrombolysis for Central Retinal Artery Occlusion in Routine Clinical Practice

Abstract Body: Background and aims
Central retinal artery occlusion (CRAO) is a rare but significantly underestimated form of ischemic stroke. There is still no definite recommendation for treatment. One of the considered and currently increasingly preferred options is intravenous thrombolysis. We present the results of a multicenter retrospective study to assess the safety and effectiveness of thrombolytic treatment in CRAO.
Methods
All patients with CRAO from six centers who received intravenous thrombolysis were included in the retrospective study. The effectiveness of the intervention was evaluated in two stages. The first stage was when the residual vision in the affected eye was achieved at least to the level of the ability to orientate in space (recognizing contours). The second stage was the improvement of vision to recognize objects and faces. The effectiveness was further evaluated depending on the duration of the difficulties before the intervention. Safety was assessed based on the symptomatic intracerebral hemorrhage.
Results
In the years 2016-2024, 32 patients (age 67.5 ± 12.9 years, 46.9% men) were treated for CRAO with intravenous thrombolysis.The median time from onset of symptoms to treatment was 6.5 hours. Within one year, 28% of patients had an ischemic stroke. Improvement after treatment occurred in 56.3% (1st degree - recognition of contours) and significant improvement in 34.4% (recognition of faces, ability to read). In patients treated within 4.5 hours, there was a significant improvement in 46%. In the case of treatment over 4.5 hours, there was a significant improvement in 26.3%. When symptoms lasted for more than eight hours, only 20% improved (at least partial improvement occurred in 46.7% of cases). Overall, intracerebral hemorrhage occurred in 6.3%. However, none of them were symptomatic. One patient had vitreous hemorrhage with subsequent correction of vision.
Conclusion
CRAO is a significantly neglected subgroup of ischemic stroke. According to our data, intravenous thrombolysis is also an effective and safe therapy here.
  • Cernik, David  ( Masaryk Hospital, Krajská zdravotní as , Usti nad Labem , Czechia )
  • Neumann, Jiri  ( County Hospital Chomutov , Chomutov , Czechia )
  • Vondrackova, Simona  ( Teplice Hospital, Krajská zdravotní as , Teplice , Czechia )
  • Vachova, Marta  ( Teplice Hospital, Krajská zdravotní as , Teplice , Czechia )
  • Macko, Jan  ( Most Hospital, Krajská zdravotní as , Most , Czechia )
  • Havlicek, Roman  ( Central Military Hospital Prag , Prag , Czechia )
  • Bikova, Sona  ( Decin Hospital, Krajská zdravotní as , Decin , Czechia )
  • Author Disclosures:
    David Cernik: DO NOT have relevant financial relationships | Jiri Neumann: DO have relevant financial relationships ; Research Funding (PI or named investigator):Bayer:Active (exists now) | Simona Vondrackova: No Answer | Marta Vachova: DO NOT have relevant financial relationships | Jan Macko: DO NOT have relevant financial relationships | Roman Havlicek: No Answer | sona bikova: No Answer
Meeting Info:
Session Info:

Acute Treatment: Systemic Thrombolysis and Cerebroprotection Posters I

Wednesday, 02/05/2025 , 07:00PM - 07:30PM

Poster Abstract Session

More abstracts on this topic:
A Case Series of Papillary Fibroelastomas on the Coumadin ridge

Aboukhatwa Omar, Akiki Elias, Kurmann Reto, Larson Kathryn, Keeney Michael, Bois Melanie, Klarich Kyle

Area Deprivation Index Associated with Time to Presentation in Acute Ischemic Stroke and Eligibility for Standard Window versus Late Presenter Thrombolysis

Fritsche Colette, Corlin Laura, Leung Lester

More abstracts from these authors:
Prolonged Low-Dose Intravenous Thrombolysis in early recurrent Stroke: ESR-PROLONG Study

Cernik David, Neumann Jiri, Vondrackova Simona, Vachova Marta, Macko Jan

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)